Pfizer to sell off Remicade biosim in EU to win Hospira deal nod; Sanofi prices Toujeo on par with Lantus in U.K.;

> Pfizer ($PFE) won E.U. approval for its $16 billion Hospira ($HSP) purchase after the company agreed to sell European rights to its biosimilar version of Remicade (infliximab). Report

> Sanofi ($SNY) priced Toujeo, its new longer-acting version of Lantus, on par with the older med in the U.K. in hopes of grabbing market share to withstand generic rivals. Report

> Over the long term, birth control pills actually protect against uterine cancer, contrary to fears that they could cause the disease, a new study found. Report

> AB Science has been studying its drug candidate masitinib in a wide swath of diseases, though it has only won approval to market the drug to treat cancer in dogs. Report

And Finally... A new analysis of anti-dementia drugs such as Eisai's Aricept found that the cholinesterase inhibitors can cause harmful weight loss. Report

Suggested Articles

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.